Axogen Stock News

Axogen (AXGN) expects FY21 revenue of $127.3M (consensus $127.79M), +13% Y/Y.4Q revenue to be $31.5M (consensus $32.05M), -3% Y/Y.4Q revenue includes $0.5M from the reversal of a…

Clinical evidence supporting the company’s platform for nerve repair will be featured in several presentations during the scientific sessions Clinical evidence supporting the company’s platform fo

Analysts expect that AxoGen, Inc. (NASDAQ:AXGN) will post ($0.13) earnings per share (EPS) for the current quarter, Zacks reports. Two analysts have provided estimates for AxoGens earnings. The lowest EPS estimate is ($0.17) and the highest is ($0.09). AxoGen posted earnings of ($0.08) per share in the same quarter last year, which suggests a negative []

Equities research analysts predict that AxoGen, Inc. (NASDAQ:AXGN) will report earnings of ($0.13) per share for the current fiscal quarter, Zacks Investment Research reports. Two analysts have issued estimates for AxoGens earnings. The lowest EPS estimate is ($0.17) and the highest is ($0.09). AxoGen reported earnings of ($0.08) per share in the same quarter last []

ALACHUA, Fla. and TAMPA, Fla., Dec. 15, 2021 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or transection to peripheral nerves, announced today that nerve repair patient Christopher (Chris) Brown has been selected to ride on the 2022 Donate Life Rose Parade Float. Additionally, organ and tissue donor Paul Flanders will be honored through a floragraph that will adorn the float. The parade will be held in Pasadena, CA on New Years Day as part of the annual Tournament of Roses ® celebration. This is the ninth year that Axogen has co-sponsored the Donate Life float to help raise awareness for the importance of organ and tissue donation.

Assenagon Asset Management S.A. lessened its stake in shares of AxoGen, Inc. (NASDAQ:AXGN) by 24.7% in the 3rd quarter, Holdings Channel.com reports. The firm owned 387,524 shares of the medical equipment provider’s stock after selling 127,253 shares during the quarter. Assenagon Asset Management S.A.’s holdings in AxoGen were worth $6,123,000 as of its most recent […]

Cubist Systematic Strategies LLC lowered its stake in AxoGen, Inc. (NASDAQ:AXGN) by 29.8% in the second quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 5,058 shares of the medical equipment providers stock after selling 2,143 shares during the quarter. Cubist Systematic Strategies LLCs holdings in AxoGen []

Exchange Traded Concepts LLC lifted its position in AxoGen, Inc. (NASDAQ:AXGN) by 21.5% in the third quarter, Holdings Channel.com reports. The institutional investor owned 206,695 shares of the medical equipment providers stock after buying an additional 36,566 shares during the period. Exchange Traded Concepts LLCs holdings in AxoGen were worth $3,266,000 at the end of []

The Nerve Conduit Market report is a valuable source of insightful data for business strategists. It provides the industry overview with growth analysis and historical & futuristic cost, revenue, demand, and supply data (as applicable). The research analysts provide an

Axogen Inc. (AXGN) shares closed today at 0.9% above its 52 week low of $9.50, giving the company a market cap of $398M. The stock is currently down 46.4% year-to-date, down 32.8% over the past 12 months, and up 9.0% over the past five years. This week, the Dow Jones Industrial Average fell 1.9%, and the S&P 500 fell 2.1%. Trading Activity Trading volume this week was 41.2% higher than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.8. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by -440.8% The company's stock price performance over the past 12 months lags the peer average by -270.6% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

AxoGen Inc. (NASDAQ:AXGN)s traded shares stood at 0.61 million during the last session, with the companys beta value hitting 0.72. At the close of trading, the stocks price was $9.76, to imply a decrease of -3.65% or -$0.37 in intraday trading. The AXGN shares 52-week high remains $23.94, putting it -145.29% down since that peak AxoGen Inc. (NASDAQ: AXGN) Loss Of -3.18% Compared To 52-Week Low; YTD Fall -45.47% What Should You Do Now? Read More »

AxoGen's (AXGN) CEO Karen Zaderej on Q3 2021 Results - Earnings Call Transcript

AxoGen (AXGN) delivered earnings and revenue surprises of 25.00% and -9.95%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Axogen (NASDAQ:AXGN) reported its Q3 earnings results on Wednesday, November 3, 2021 at 04:00 PM. Here's what investors need to know about the announcement.

ALACHUA, Fla. and TAMPA, Fla., Oct. 13, 2021 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or transection to per